Lantheus (LNTH) Analyzed By Cantor Fitzgerald with $22.0000 Target, Intec Pharma Limited Ord (NTEC) Shorts Decreased By 50%

July 17, 2017 - By Nellie Frank

Among 5 analysts covering Lantheus Holdings (NASDAQ:LNTH), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Lantheus Holdings has $1800 highest and $4 lowest target. $9’s average target is -48.72% below currents $17.55 stock price. Lantheus Holdings had 10 analyst reports since August 31, 2015 according to SRatingsIntel. The stock of Lantheus Holdings Inc (NASDAQ:LNTH) has “Neutral” rating given on Friday, September 23 by Credit Suisse. The firm has “Neutral” rating by Credit Suisse given on Friday, December 11. Wells Fargo downgraded the stock to “Market Perform” rating in Wednesday, September 30 report. Jefferies maintained the shares of LNTH in report on Thursday, June 29 with “Buy” rating. Jefferies maintained Lantheus Holdings Inc (NASDAQ:LNTH) rating on Monday, August 29. Jefferies has “Buy” rating and $12 target. The firm earned “Outperform” rating on Wednesday, February 24 by RBC Capital Markets. The stock has “Neutral” rating by Robert W. Baird on Monday, August 31.

Intec Pharma Limited Ord (NASDAQ:NTEC) had a decrease of 50% in short interest. NTEC’s SI was 1,300 shares in July as released by FINRA. Its down 50% from 2,600 shares previously. The SI to Intec Pharma Limited Ord’s float is 0.01%. The stock decreased 1.79% or $0.1 on July 14, reaching $5.5. About shares traded. Intec Pharma Ltd (NASDAQ:NTEC) has risen 51.00% since July 17, 2016 and is uptrending. It has outperformed by 34.30% the S&P500.

Analysts await Lantheus Holdings Inc (NASDAQ:LNTH) to report earnings on August, 3. They expect $0.24 earnings per share, 0.00% or $0.00 from last year’s $0.24 per share. LNTH’s profit will be $8.61 million for 18.28 P/E if the $0.24 EPS becomes a reality. After $0.28 actual earnings per share reported by Lantheus Holdings Inc for the previous quarter, Wall Street now forecasts -14.29% negative EPS growth.

The stock decreased 3.84% or $0.7 on July 14, reaching $17.55. About shares traded. Lantheus Holdings Inc (NASDAQ:LNTH) has risen 644.29% since July 17, 2016 and is uptrending. It has outperformed by 627.59% the S&P500.

Lantheus Holdings, Inc. is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The company has market cap of $629.76 million. The Company’s imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging. It has a 28.86 P/E ratio. It operates in two divisions: U.S.

Intec Pharma Ltd is an Israel-based drug development company. The company has market cap of $75.56 million. It is a development stage biopharmaceutical firm that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. It currently has negative earnings. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.